Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us

Trump administration rejects Biden’s proposal for Medicare and Medicaid weight loss drug coverage

The news: The Trump administration is not proceeding with a Biden administration proposal to have Medicare and Medicaid cover GLP-1 medications for weight loss.

Catch up quick: Medicare is prohibited by law from covering anti-obesity medications for weight loss alone, though beneficiaries could get insurance coverage for some GLP-1s if prescribed for diabetes, heart disease, and sleep apnea. About three-quarters of US states don’t cover GLP-1s for Medicaid when used just for obesity, per KFF data as of August 2024.

Why it matters: Medicare and Medicaid GLP-1 drug coverage for weight loss would considerably drive down costs for patients but would cost the government billions each year.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!